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Purpose of Project: Gut dysfunction in children in resource-poor environments is well 
documented. The precipitant of this dysfunction is unknown. However, infections, nonspecific 
inflammation, malabsorption, and leakiness of mucosa are frequently incriminated as processes 
that underlie this dysfunction. Major consequences of this dysfunction have been postulated, the 
most critical of which is poor growth, especially stunting. The study of gut dysfunction in children 
would have as its ultimate goal the prevention of growth consequences. In this project, we have 
collated literature published between 2000 and 2010, with the purpose of guiding near-term 
research into the causes and pathophysiology of enteric dysfunction. In particular, we have 
attempted to identify biomarkers with which to detect this dysfunction. 
Rationale for seeking biomarkers: Theoretically, tissue from the small bowel, the organ of 
greatest interest, could shed light on the underlying pathophysiology. However, analyzing this 
tissue poses challenges. These challenges include the practicalities of gaining access to this 
organ, incomplete confidence regarding sampling strategies to pursue, risk of sampling error, 
and the yet-to-be-determined value of the information that would be obtained. Thus, the more 
readily obtained and potentially more informative biomarkers found in stool or blood could 
feasibly advance the field.  
Methods: A systematic literature review was performed by trained research analysts, two 
physicians, and two epidemiologists. Materials were collated in a master, highly inclusive 
database of publications relevant to environmental enteric dysfunction (EED) in children in 
resource-poor settings. This process was undertaken for two reasons. First, because search 
terms sensitive and specific for “enteropathy” and “enteric dysfunction” are not well indexed in 
literature databases (including PubMed), we had to create a resource with which to find data 




related to the topic. Development of an internal library was the most efficient preparation for 
multiple interrogations, including those seeking to identify publications relevant to the following 
systematic review question, which is a main focus of this book: 
What biomarkers or diagnostic tests have been used to identify, or have been shown to 
be associated with, mucosal dysfunction of the small intestine or host inflammation in 
children less than five years of age from developing-country settings? 
Findings: 67,903 unique references were obtained from PubMed, Embase, Global Health and 
World Health Organization (WHO) Regional Libraries (1980-2010). 9,675 of these publications 
met EED Library inclusion criteria and 374 between 2000 and 2010 were potentially relevant to 
the systematic review question. Of these, 77 met the review inclusion criteria. 
Each relevant publication was thoroughly and systematically reviewed and summarized in 
evidence table format. Biomarkers were categorized as being relevant to one of eight processes 
that could underlie, be associated with, or reflect enteric function/dysfunction in children: (1) 
absorption; (2) porosity/permeability; (3) digestion; (4) intestinal inflammation and/or intestinal 
immune activation; (5) systemic inflammation and/or systemic immune activation; (6) microbial 
drivers; (7) nonspecific intestinal injury, and (8) non-small intestinal organ function. A meta- 
analysis of pooled data from these publications was not possible because of the heterogeneity 
of study populations and methods, non-standardized information portrayal, scant attempts to 
correlate biomarkers to intestinal pathology (and where this was attempted, correlation was 
lacking), small population sizes, and limited relation of biomarkers with outcomes of interest, 
i.e., stunting. However, the data do strongly suggest the presence of broad categories of 
intestinal dysfunction, and imply a high prevalence of poorly functioning guts, in children in 
resource-poor environments. It is quite likely that a panel of biomarkers reflecting multiple 




Conclusions: Our novel search and EED construction methodology effectively identified a 
diffusely defined and poorly indexed (in the literature)—but nevertheless important—public 
health problem. Our EED Library format permits efficient information retrieval for multiple EED-
related inquiries and the methodology can be applied to other health issues that face similar 
definition and search/retrieval issues.  
Using this comprehensive data collation and extraction system, we found no evidence of a 
globally applicable, simple, single-purpose biomarker that reliably correlates with intestinal 
dysfunction in children or to growth faltering mediated by such a lesion. The studies that are 
available were often not performed with this goal in mind. However, there is a large body of 
evidence that enteric dysfunction in children is highly prevalent in resource-poor settings, and 
that this dysfunction could be an important, and potentially remediable, cause of stunting. 
Therefore, we urge that future research on biomarkers in human populations be pursued. We 
also urge that future work adheres to the following principles: 
1. Assess function-related candidate biomarkers. 
2. Relate the biomarker data to consequential outcomes. 
3. Rigorously describe the study design and methodology underlying the data produced. 
4. Provide robust data repositories. Employ best practices publication guidelines, such as 
those endorsed by the Consolidated Standards of Reporting Trials (CONSORT) system 
including the Standards for Reporting of Diagnostic Accuracy (STARD) Initiative. 
5. Consider indices of enteric dysfunction, incorporating “stacking” multiple biomarkers 
representing diverse pathophysiologic processes, potentially also including non-
laboratory test derived clinical characteristics. 
6. Explore invasive, field-adaptable, host assessments (e.g., saliva, transcutaneous), even 
if technology needs to be developed or adapted. 
